LYVE1 and lymphangiosarcoma: Additionally, our findings reveal that SOX18 inhibition by Sm4 results in a decrease in lymphatic phenotype key markers (PROX1, VEGFR3, and LYVE1), indicating a potential role for SOX18 in promoting cancer‐related lymphangiogenesis as well as lymphangiosarcoma development and progression.